Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer.

摘要: Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid that is potent inhibitor of mitotic microtubule polymerization, was recently approved for the treatment non-small cell lung cancer. Radiotherapy also has been widely used to treat this malignancy. Since other antitumor agents act on microtubules, such as paclitaxel and estramustine, have shown radiosensitizers, we studied ability vinorelbine potentiate radiation. The in vitro activity combination evaluated human carcinoma lines NCI-H460 A549. when cells were exposed 24 hours then irradiated (1 6 Gy) drug potentiated radiation dose-dependent manner, with ratio fractional survival (radiation) (drug plus radiation) ranging from 1.7:1 at 1 Gy 5.5:1 Gy. When sequence reversed (ie, followed by exposure), similar ratios obtained concentrations five 10 times lower. In line produced block G2/M phase cycle, maximum (60% 70%) occurring after treatment. greatest potentiation seen they had plateaued cycle. given early irradiation, only 10% 30% G2/M, those controls treated alone. A549 induced G1 block. case, unable effects These studies show can cycle-dependent, maximal effect being are G2 phase.